These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38270332)

  • 1. What is the best first choice oral drug therapy for OAB?
    Sahai A; Robinson D; Abrams P; Wein A; Malde S
    Neurourol Urodyn; 2024 Aug; 43(6):1328-1336. PubMed ID: 38270332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.
    Gratzke C; Chapple C; Mueller ER; Robinson D; Rolland C; Staskin D; Stoelzel M; Maanen RV; Siddiqui E
    Eur Urol; 2019 Dec; 76(6):767-779. PubMed ID: 31416636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence and compliance with medication management in the treatment of overactive bladder.
    Kim TH; Lee KS
    Investig Clin Urol; 2016 Mar; 57(2):84-93. PubMed ID: 26981589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging drugs for overactive bladder.
    Karmarkar R; Khullar V
    Expert Opin Emerg Drugs; 2015; 20(4):613-24. PubMed ID: 26359223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.
    Mitcheson HD; Samanta S; Muldowney K; Pinto CA; Rocha BA; Green S; Bennett N; Mudd PN; Frenkl TL
    Eur Urol; 2019 Feb; 75(2):274-282. PubMed ID: 30661513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review.
    Yeowell G; Smith P; Nazir J; Hakimi Z; Siddiqui E; Fatoye F
    BMJ Open; 2018 Nov; 8(11):e021889. PubMed ID: 30467131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization rate and long-term persistence of combination pharmacotherapy with β3-agonists and antimuscarinics for overactive bladder refractory to monotherapy in a real-world setting.
    Soda T; Koike S; Ikeuchi R; Okada T
    Neurourol Urodyn; 2022 Jun; 41(5):1165-1171. PubMed ID: 35419862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical pharmacology of the medical treatment for overactive bladder in adults.
    Mostafaei H; Shariat SF; Salehi-Pourmehr H; Janisch F; Mori K; Quhal F; Hajebrahimi S
    Expert Rev Clin Pharmacol; 2020 Jul; 13(7):707-720. PubMed ID: 32500759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current optimal pharmacologic therapies for overactive bladder.
    Jiang YH; Kuo HC
    Expert Opin Pharmacother; 2023; 24(18):2005-2019. PubMed ID: 37752121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.
    Giarenis I; Robinson D; Cardozo L
    Drugs; 2015 Oct; 75(15):1707-13. PubMed ID: 26323339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Pharmacologic Management of Overactive Bladder Syndrome: Where Do We Stand?
    Marcelissen T; Rashid T; Antunes Lopes T; Delongchamps NB; Geavlete B; Rieken M; Cornu JN; Rahnama'i MS;
    Eur Urol Focus; 2019 Nov; 5(6):1112-1119. PubMed ID: 29625926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A drug safety evaluation of mirabegron in the management of overactive bladder.
    Robinson D; Thiagamoorthy G; Cardozo L
    Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex.
    Chapple CR; Mironska E; Wagg A; Milsom I; Diaz DC; Koelbl H; Pushkar D; Tubaro A; De Ridder D; Chartier-Kastler E; Phillips LD
    Eur Urol Focus; 2020 May; 6(3):522-530. PubMed ID: 31623981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
    Wagg A; Compion G; Fahey A; Siddiqui E
    BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy.
    Shin JH; Kim A; Choo MS
    Investig Clin Urol; 2017 Jul; 58(4):261-266. PubMed ID: 28681036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of an α
    Herschorn S; Tarcan T; Jiang YH; Chung E; Abdul Hadi F; Steup A; Sumarsono B
    Neurourol Urodyn; 2024 Mar; 43(3):604-619. PubMed ID: 38291827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel.
    Farag F; Sakalis VI; Arteaga SM; Sihra N; Karavitakis M; Arlandis S; Bø K; Cobussen-Boekhorst H; Costantini E; de Heide M; Groen J; Peyronnet B; Phé V; van Poelgeest-Pomfret ML; van den Bos TWL; van der Vaart H; Harding CK; Carmela Lapitan M; Imran Omar M; Nambiar AK
    Eur Urol; 2023 Sep; 84(3):302-312. PubMed ID: 37331921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.